The GLP-1 Revolution: Highlighting the Impact of Incretin-Based Therapies on Metabolic Health
The introduction of drugs acting on the Glucagon-Like Peptide-1 (GLP-1) pathway has fundamentally reshaped the landscape of the endocrinology therapeutic domain over the last decade. GLP-1 receptor agonists, such as Semaglutide and Dulaglutide, mimic the action of natural incretin hormones, stimulating insulin secretion, inhibiting glucagon release, and, crucially, slowing gastric emptying....
0 Comments 0 Shares 93 Views 0 Reviews